Anaphylaxis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major anaphylaxis markets are expected to exhibit a CAGR of 5.85% during 2024-2034.
The anaphylaxis market has been comprehensively analyzed in IMARC's new report titled "Anaphylaxis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anaphylaxis refers to a severe and potentially life-threatening allergic reaction that develops rapidly after exposure to an allergen. In this condition, the body's immune system releases a flood of chemicals, such as histamine, which can cause a range of indications throughout the body. These symptoms may include itching, redness, and swelling on the skin, difficulty breathing, wheezing, coughing, tightness in the chest, a rapid or weak pulse, low blood pressure, dizziness or fainting, nausea, vomiting, abdominal pain, diarrhea, etc. In some cases, individuals suffering from the ailment may also experience anxiety, a sense of impending doom, and confusion. The diagnosis of anaphylaxis is typically based on a combination of clinical features, a physical examination, and the patient's medical history. Various blood workups are also utilized to measure certain substances in the blood, such as tryptase and histamine levels, that are associated with allergic reactions. The healthcare provider may further perform skin prick or intradermal tests, in which small amounts of suspected allergens are applied to the skin to identify specific toxins causing the underlying symptoms.
The rising prevalence of insect stings, including those from bees, wasps, fire ants, etc., that trigger the release of various chemicals, like histamine and numerous other mediators, into the bloodstream is primarily driving the anaphylaxis market. In addition to this, the increasing incidence of mast cell disorders, in which the immune system mistakenly attacks the body's tissues, leading to inflammation, is creating a positive outlook for the market. Moreover, the widespread adoption of epinephrine therapy, since it works quickly to constrict blood vessels, relax smooth muscles, and decrease the severity of allergic reactions, is further bolstering the market growth. Apart from this, the inflating application of corticosteroids, such as prednisone and methylprednisolone, on account of their several advantages, like reducing inflammation, preventing the risk of late-phase symptoms, enhancing the quality of life, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced autoinjector devices that are designed with features, including visual cues and audio instructions, making them easier for non-medical bystanders to use in an emergency, is expected to drive the anaphylaxis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the anaphylaxis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for anaphylaxis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anaphylaxis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the anaphylaxis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the anaphylaxis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current anaphylaxis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the anaphylaxis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the anaphylaxis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the anaphylaxis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of anaphylaxis across the seven major markets?
What is the number of prevalent cases (2018-2034) of anaphylaxis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of anaphylaxis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with anaphylaxis across the seven major markets?
What is the size of the anaphylaxis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of anaphylaxis?
What will be the growth rate of patients across the seven major markets?
The anaphylaxis market has been comprehensively analyzed in IMARC's new report titled "Anaphylaxis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anaphylaxis refers to a severe and potentially life-threatening allergic reaction that develops rapidly after exposure to an allergen. In this condition, the body's immune system releases a flood of chemicals, such as histamine, which can cause a range of indications throughout the body. These symptoms may include itching, redness, and swelling on the skin, difficulty breathing, wheezing, coughing, tightness in the chest, a rapid or weak pulse, low blood pressure, dizziness or fainting, nausea, vomiting, abdominal pain, diarrhea, etc. In some cases, individuals suffering from the ailment may also experience anxiety, a sense of impending doom, and confusion. The diagnosis of anaphylaxis is typically based on a combination of clinical features, a physical examination, and the patient's medical history. Various blood workups are also utilized to measure certain substances in the blood, such as tryptase and histamine levels, that are associated with allergic reactions. The healthcare provider may further perform skin prick or intradermal tests, in which small amounts of suspected allergens are applied to the skin to identify specific toxins causing the underlying symptoms.
The rising prevalence of insect stings, including those from bees, wasps, fire ants, etc., that trigger the release of various chemicals, like histamine and numerous other mediators, into the bloodstream is primarily driving the anaphylaxis market. In addition to this, the increasing incidence of mast cell disorders, in which the immune system mistakenly attacks the body's tissues, leading to inflammation, is creating a positive outlook for the market. Moreover, the widespread adoption of epinephrine therapy, since it works quickly to constrict blood vessels, relax smooth muscles, and decrease the severity of allergic reactions, is further bolstering the market growth. Apart from this, the inflating application of corticosteroids, such as prednisone and methylprednisolone, on account of their several advantages, like reducing inflammation, preventing the risk of late-phase symptoms, enhancing the quality of life, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced autoinjector devices that are designed with features, including visual cues and audio instructions, making them easier for non-medical bystanders to use in an emergency, is expected to drive the anaphylaxis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the anaphylaxis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for anaphylaxis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anaphylaxis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the anaphylaxis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the anaphylaxis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current anaphylaxis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the anaphylaxis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the anaphylaxis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the anaphylaxis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of anaphylaxis across the seven major markets?
What is the number of prevalent cases (2018-2034) of anaphylaxis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of anaphylaxis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with anaphylaxis across the seven major markets?
What is the size of the anaphylaxis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of anaphylaxis?
What will be the growth rate of patients across the seven major markets?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANAPHYLAXIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023)and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANAPHYLAXIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANAPHYLAXIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ANAPHYLAXIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANAPHYLAXIS - UNMET NEEDS
10 ANAPHYLAXIS - KEY ENDPOINTS OF TREATMENT
11 ANAPHYLAXIS - MARKETED PRODUCTS
11.1 List of Anaphylaxis Marketed Drugs Across the Top 7 Markets
11.1.1 Symjepi (Epinephrine pre-filled syringe) - Adamis Pharmaceuticals Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Auvi Q (Epinephrine self-injectable) - Kaleo
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Adrenalin (Epinephrine injection) - Par Sterile Products
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ANAPHYLAXIS - PIPELINE DRUGS
12.1 List of Anaphylaxis Pipeline Drugs Across the Top 7 Markets
12.1.1 AQST-108 - Aquestive Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ANAPHYLAXIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ANAPHYLAXIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANAPHYLAXIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Anaphylaxis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Anaphylaxis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Anaphylaxis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Anaphylaxis - Market Size by Therapies
15.3.2.1 Market Size by Therapies(2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Anaphylaxis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Anaphylaxis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Anaphylaxis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Anaphylaxis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Anaphylaxis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Anaphylaxis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Anaphylaxis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Anaphylaxis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Anaphylaxis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Anaphylaxis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Anaphylaxis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Anaphylaxis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Anaphylaxis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Anaphylaxis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Anaphylaxis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Anaphylaxis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Anaphylaxis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Anaphylaxis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Anaphylaxis - Access and Reimbursement Overview
16 ANAPHYLAXIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANAPHYLAXIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANAPHYLAXIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANAPHYLAXIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023)and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANAPHYLAXIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANAPHYLAXIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ANAPHYLAXIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANAPHYLAXIS - UNMET NEEDS
10 ANAPHYLAXIS - KEY ENDPOINTS OF TREATMENT
11 ANAPHYLAXIS - MARKETED PRODUCTS
11.1 List of Anaphylaxis Marketed Drugs Across the Top 7 Markets
11.1.1 Symjepi (Epinephrine pre-filled syringe) - Adamis Pharmaceuticals Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Auvi Q (Epinephrine self-injectable) - Kaleo
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Adrenalin (Epinephrine injection) - Par Sterile Products
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ANAPHYLAXIS - PIPELINE DRUGS
12.1 List of Anaphylaxis Pipeline Drugs Across the Top 7 Markets
12.1.1 AQST-108 - Aquestive Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ANAPHYLAXIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ANAPHYLAXIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANAPHYLAXIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Anaphylaxis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Anaphylaxis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Anaphylaxis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Anaphylaxis - Market Size by Therapies
15.3.2.1 Market Size by Therapies(2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Anaphylaxis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Anaphylaxis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Anaphylaxis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Anaphylaxis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Anaphylaxis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Anaphylaxis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Anaphylaxis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Anaphylaxis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Anaphylaxis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Anaphylaxis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Anaphylaxis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Anaphylaxis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Anaphylaxis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Anaphylaxis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Anaphylaxis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Anaphylaxis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Anaphylaxis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Anaphylaxis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Anaphylaxis - Access and Reimbursement Overview
16 ANAPHYLAXIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANAPHYLAXIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANAPHYLAXIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
